RxDoctor Payments Data

Esther Chijioke, MD

Geriatric Medicine · New York, NYNPI 1871927798

Payments from drug & device makers

$571in general payments, 2019–2025

Across 40 payments — averaging $14.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$328
  • Otsuka America Pharmaceutical, Inc.$130
  • Acadia Pharmaceuticals Inc$39
  • AstraZeneca$38
  • Gilead$23
  • UCB, Inc.$13

What the payments were for

  • Food & beverage$571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$571 in reported general payments places this provider in the 75th percentile of 400 geriatric medicine providers in New York.

See all geriatric medicine providers in New York

Medicare billing

Part B allowed, 2024
$651,511
Medicare patients
199
Services billed
5,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$106,630
TivicayDolutegravir Sodium87$96,999
NuedextaDextromethorphan Hbr/Quinidine123$93,926
BiktarvyBictegrav/Emtricit/Tenofov Ala20$83,461
TriumeqAbacavir/Dolutegravir/Lamivudi20$78,355
XifaxanRifaximin22$34,149
RexultiBrexpiprazole44$33,169
TrulicityDulaglutide48$29,979
OzempicSemaglutide27$27,691
JardianceEmpagliflozin85$25,611
OpzeluraRuxolitinib Phosphate11$23,973
JanuviaSitagliptin Phosphate80$23,319
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,755
TradjentaLinagliptin62$16,474
SantylCollagenase Clostridium Hist.29$15,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$328$93,926123 claims
GileadBiktarvy$23$83,46120 claims
Otsuka America Pharmaceutical, Inc.Rexulti$130$33,16944 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 400 geriatric medicine providers in New York.

Other geriatric medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →